We have investigated the molecular target of an antitumor agent ICRF-193, a bisdioxopiperazine derivative, inin vitrochromosome condensation system ofXenopusegg extract (XEE), where DNA topoisomerase II was previously demonstrated to play a crucial role. DemembranatedXenopussperm head chromatin is converted to metaphase chromosome-like structure in XEE in two steps,i.e.,swelling of the chromatin followed by condensation of chromosome. When ICRF-193 was added to the reaction, swelling of the chromatin was not affected but chromosome condensation was completely blocked. This blockade was reversed by exogenous supplement of calf thymus topoisomerase II, which was in turn neutralized by anti-topoisomerase II monoclonal antibody. These results demonstrate that topoisomerase II is the molecular target of the drug ICRF-193.